Bristol Myers Squibb sues Amgen over Opdivo biosimilar as $10bn franchise nears patent cliff
Bristol Myers Squibb and Ono Pharmaceutical are suing Amgen over seven patents tied to its proposed Opdivo biosimilar ABP 206, opening an important legal battle around a cancer drug that generated more than $10 billion in 2025.